While many pharma companies have integrated digital tools like cloud services into their operations, some are later adopters. Boehringer Ingelheim is one of the most recent companies to announce a move to a cloud-based R&D platform as part of the company’s commitment to digital transformation. For those still considering how to go about the shift to digital, rolling things out in the right order is one important factor, an EY expert tells In Vivo.

Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.